This article originally appeared in The Motley Fool on December 2, 2004. By explicitly considering the odds of a company growing faster than expected, investors can reduce the agony of watching share price and earnings-per-share trends diverge. Here are some mainstream ideas to get started in the right direction. Buying and holding companies with growing earnings per share… Read More »
MoneyMatters Blog
"In the investing blog, I seek to help you take sound investment decisions free from emotion by sharing my objective insights on markets, sectors, and companies."
Sam Subramanian PhD, MBA, Editor, AlphaProfit MoneyMatters
What’s Driving Biotech
Biotechnology, which has been on a roll, declined after the much-anticipated American Society of Clinical Oncologists meeting in early June in New Orleans, where cancer specialists deliberated on the merits of new treatments. The two extant ETFs which focus on this industry are iShares Nasdaq Biotechnology (AMEX:IBB) and Biotech HOLDRs (AMEX:BBH). Before deciding to dump or load up… Read More »
Playing the High-Stakes Biotech Game
Investing in biotech stocks has never been for the faint-hearted as many biotech companies have high cash burn rates. The biotech industry however has a few things going for it. Read on to learn more about investment opportunities in this industry. Shares of biotechnology companies have declined, after the much anticipated American Society of Clinical Oncologists meeting in… Read More »
Fidelity No Load Mutual Funds: Supercharge Your Portfolio’s Returns
Investors who exclusively use broadly diversified, no load mutual funds for their stock investments often lose out on opportunities to increase the reward potential of their portfolios. This article looks at two methods investors may use to enhance the performance of their portfolio of diversifed, no load mutual funds. Diversify, diversify, diversify! Rebalance your portfolio periodically. These have… Read More »
Biotech Funds FBIOX
The favorable dynamics for the Biotechnology industry is attracting investor attention. On the heels of recent gains, there are reasons to be optimistic on continued out-performance. An efficient Food and Drug Administration, progress on extension of new products, trouble in ‘major pharma’ land and reasonable valuation create a favorable milieu for investing in the biotechnology sector. These conditions… Read More »
New ETF Recommendations
New ETF Recommendations
The AlphaProfit ETF style rotation model portfolio will be reconstituted with new recommendations on Wednesday, February 19. Learn more about AlphaProfit's Free and Premium Service investment newsletters.
Free Investment Newsletter MoneyMatters
- Independent analysis of the economy, markets, and sectors
- Unbiased ETF, stock, and mutual fund advice and evaluations
- Unique insights on emerging profit opportunities and must-know threats
- Complimentary access to premium service
- Subscription discounts for premium service

- Five Smart Ways of Using Sector Funds and ETFs with inside scoop on sector investments
- Three Key Mistakes to Avoid when Investing in Sector ETFs
Premium Service Investment Newsletter
Clear, Actionable Advice on Sectors, Funds, ETFs, & Stocks
- Specific guidance on what and when to buy or sell
- Long-term investing and short-term trading recommendations
- Proven strategies for all markets
- 75% win-rate including 2008 crash and dot-com bust
Market-beating model portfolios
- Suitable for small and large accounts sizes
- Appropriate for different investment objectives and account types
- Results verifiable in login area with free account
- Track record of smashing market 7-to-1
Priceless intangibles
- All recommendations provided ahead of time with ample notice
- Unbiased, independent advice with no axes to grind
- 24/7 access to premium service and its archives
- Access to Dr. Sam Subramanian via e-mail
THE GOOD NEWS JUST BEGINS!